Reportlinker Adds the Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies

Jan 19, 2010, 07:37 ET from Reportlinker

NEW YORK, Jan. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Gastrointestinal Market Outlook To 2014: Market dynamics, competitive landscape, emerging therapies

http://www.reportlinker.com/p0172204/The-Gastrointestinal-Market-Outlook-To-2014-Market-dynamics-competitive-landscape-emerging-therapies.html

Gastrointestinal disorders are quite diverse affecting different parts of the alimentary tract such as the pancreas, oropharynx, liver and biliary system and the alimentary canal. Causes of these disorders vary and could include genetic anomalies, the effect of certain toxins and drugs, infections, cancer and often unknown causes. Disorders of the gastrointestinal tract (GIT) are fairly common and occur in people of all ages. These disorders take up a significant share of the disease burden in developed economies and the gravity of the problem is further accentuated by the difficulty that they pose in effective management. GIT therapy area consists of some indications that can be treated through pharmacologic interventions, though significant unmet need still exists. These unmet medical needs are more common for indications such as irritable bowel syndrome (IBS), Crohn's disease (CD) and ulcerative colitis (UC). An incomplete understanding of the etiologies of these diseases limits their effective treatment, leading to misguided treatment and misdiagnosis. A significant fraction of the drugs used in the GIT therapy area are for the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). The therapy area overall, however, reflects significant levels of genericization with R&D efforts drifting towards novel therapies for Crohn's disease and inflammatory bowel disease (IBD). In several instances though, the shift could be out of GIT to the faster growing therapy areas such as oncology, cardiovascular disorders and autoimmune disorders.

The gastrointestinal market was valued at $49.9bn in 2008 and US took the largest share of this market (37.8%) with sales amounting to $18.8bn. The gastrointestinal market reflects a high degree of genericization and is quite mature. The other three categories of brands ($23.7bn) captured almost as much in sales as original and licensed brands together ($26.3bn), a trend much in contrast to the high-growth therapy areas such as diabetes and oncology, where genericization is less prevalent. The growth of the GI therapeutic area has so far hinged on the performance of the PPI drug class. The interplay of brands within this drug class has shaped the market dynamics. Over the forecast period, the GI market's growth will be determined by the growth of the immunosuppressants and antirheumatic agents. These two drug classes are led by biologics such as Remicade and Humira, which are less prone to genericization and with the appearance of newer agents such as Cimzia, the market is expected to expand further. This report provides an overview of key events in the global gastrointestinal market that have impacted treatment trends and sales potential.

Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios can be obtained using this report.

Scope of this report

Epidemiological analysis of the therapy area and forecast prevalence over the period 2009-14

Forecasts and analysis of the key products in the gastrointestinal market over the period 2009-14 across major classes of treatments

Detailed analysis across major classes of gastrointestinal treatment including immunosuppressants and anti-rheumatic agents

Detailed analysis of the clinically differentiated products in the gastrointestinal market pipeline and sales forecast of key R&D pipeline products in the global gastrointestinal market

Key findings from this report

Growth in the Crohn's disease and ulcerative colitis market is likely to be driven by self-injectable products. This would lead to the transition of a significant proportion of patients on Remicade therapy to these products. The convenience of self-injection would help in driving growth in this category while facilitating earlier use of drugs. These dynamics have the potential to fuel growth while expanding the market in these categories.

AstraZeneca has constituted a new company, which will be funded by three private equity firms, with several of its gastrointestinal programs. This new biotech venture of the company, called Albireo, has taken up one early stage clinical program, besides some preclinical programs of the company. The private equity firms involved are – TVM Capital, Phase4 Ventures and Scottish Widows Investment Partnership. This new venture of AstraZeneca is a bid towards streamlining its gastrointestinal development projects in key indications such as GERD and for line extensions of its market leading product Nexium.

Many of the top ten players posted a decline in sales over 2007, a fact indicative of the high degree of genericization in the market. Over all, drugs indicated for the treatment of ulcer are expected to drag down the sales of most players. Thus, companies that have maintained a more diverse drug class portfolio are expected to gain more in the long run.

Use this report to:

Develop insights into patient potential with the report's coverage of the therapy area and top ten leading gastrointestinal players today.

Quickly understand how recent events are affecting the performance of major products, and how leading players are confronting competitive challenges in the gastrointestinal marketplace.

Gain up-to-date market intelligence across the gastrointestinal category and understand the major issues affecting key pharmaceutical marketers.

Understand which drug classes have the greatest potential to drive gastrointestinal franchise growth, and how pharmaceutical companies are attempting to capitalize these market opportunities.

Compare the franchises of leading pharmaceutical companies across key therapeutic classes and understand how market share of leading companies will evolve over the next six years.

The Gastrointestinal Market Outlook to 2014

Executive summary 10

Patient potential 10

Gastrointestinal market dynamics 11

Key investigational compounds 12

Leading players of the gastrointestinal market 13

Scope and methodology 14

Scope 14

Methodology 14

Scope of IMS data 15

Chapter 1 Patient potential 18

Summary 18

Introduction 19

Gastroesophageal reflux disease (GERD) 20

Overview 20

Diagnosis, treatment and management 21

Epidemiology 22

Forecast epidemiology 22

Peptic ulcer disease (PUD) 24

Overview 24

Diagnosis, treatment and management 24

Epidemiology 25

Forecast epidemiology 27

Irritable bowel syndrome (IBS) 28

Overview 28

Diagnosis, treatment and management 28

Epidemiology 30

Forecast epidemiology 31

Ulcerative colitis (UC) 32

Overview 32

Diagnosis, treatment and management 32

Epidemiology 33

Forecast epidemiology 34

Crohn's disease (CD) 35

Overview 35

Diagnosis, treatment and management 35

Epidemiology 36

Forecast epidemiology 37

Chapter 2 Gastrointestinal market dynamics 40

Summary 40

Introduction 41

Market analysis by country 41

Licensing trends 42

Key recent events 44

AstraZeneca's GI programs part of a new biotech venture 44

Kosan Biosciences licenses a preclinical program to Pfizer 45

Xifaxan to be filed for IBS 45

Dextofisopam fails in Phase IIb 46

PPI interaction with clopidogrel could adversely affect its sales 46

Market analysis by drug class 46

The GERD treatment cascade 48

Proton pump inhibitors 49

Nexium (esomeprazole): AstraZeneca 50

Takepron (lansoprazole): Takeda 53

H2RAs 54

Gaster/Pepcid (famotidine): Astellas 56

Intestinal anti-inflammatories 56

Serotonin antagonists 59

Antispasmodics/anticholinergics 61

Inflammatory bowel disease: Crohn's disease, ulcerative colitis 62

Drug classes used for IBD 63

Leading brands used in the treatment of IBD 63

Others 66

Laxatives: A snapshot of chronic constipation 66

Therapy area sales forecast 70

Leading brands 71

Leading brands forecast 72

Chapter 3 Key investigational compounds 74

Summary 74

Introduction 75

Recent R&D updates 75

Renzapride discontinued 75

Adolor to pursue OBD drug development in spite of the Entereg setback 76

Calmactin not to be pursued further for FDA approval 76

Injectable products to drive growth in the Crohn's and UC market 77

Rezonic receives complete response letter 77

Gastrointestinal market R&D 77

A snapshot of key pipeline compounds 78

Entereg (alvimopan): Adolor/GSK 78

Overview 78

Mechanism of action 79

Clinical 79

Marketing and regulatory 80

Relistor (methylnaltrexone): Wyeth/Progenics 80

Overview 80

Mechanism of action 81

Clinical 81

Marketing and regulatory 82

Kapidex /TAK-390MR (dexlansoprazole): Takeda 82

Overview 82

Mechanism of action 82

Clinical 83

Regulatory 83

Issues/competitive landscape 84

Linaclotide: Forest/Ironwood/ Almirall 84

Overview 84

Mechanism of action 84

Clinical 85

Regulatory 85

Issues/competitive landscape 86

Cimzia (certolizumab): UCB Pharma 86

Overview 86

Clinical 86

Regulatory 87

Issues/competitive landscape 87

Key investigational compounds sales forecast 88

Chapter 4 Leading players of the

gastrointestinal market 90

Summary 90

Introduction 91

AstraZeneca 93

Overview 93

Drug class focus 94

Marketed products portfolio 94

R&D pipeline analysis 95

Strategic growth analysis 96

Drivers of growth 96

Resistors of growth 97

Takeda 98

Overview 98

Drug class focus 98

Marketed products portfolio 99

R&D pipeline analysis 101

Strategic growth analysis 102

Drivers of growth 102

Resistors of growth 102

Eisai 103

Overview 103

Drug class focus 103

Marketed products portfolio 104

R&D pipeline analysis 105

Strategic growth analysis 105

Drivers of growth 105

Resistors of growth 106

Nycomed 106

Overview 106

Drug class focus 106

Marketed products portfolio 107

R&D pipeline analysis 108

Strategic growth analysis 109

Drivers of growth 109

Resistors of growth 109

Wyeth 110

Overview 110

Drug class focus 110

Marketed products portfolio 111

R&D pipeline analysis 113

Strategic growth analysis 114

Drivers of growth 114

Resistors of growth 115

Johnson & Johnson 115

Overview 115

Drug class focus 116

Marketed products portfolio 117

R&D pipeline analysis 117

Strategic growth analysis 118

Drivers of growth 118

Resistors of growth 119

Growing generic incursion in the GI market 119

Leading players' outlook through to 2014 121

Chapter 5 Appendix 122

IMS data 122

Glossary 123

Index 125

List of Figures

Figure 2.1: Global GI market sizes, 2008 42

Figure 2.2: GI market breakdown by licensing status, 2007–08 44

Figure 2.3: Drug classes CAGR comparison, 2004–08 48

Figure 2.4: Mechanism of action of mesalazine 58

Figure 4.5: Competitive dynamics of the top 10 GI market players, 2004–08 92

Figure 4.6: Drug class focus of AstraZeneca ($m), 2008 94

Figure 4.7: Drug class focus of Takeda ($m), 2008 99

Figure 4.8: Drug class focus of Eisai ($m), 2008 103

Figure 4.9: Drug class focus of Nycomed ($m), 2008 107

Figure 4.10: Drug class focus of Wyeth ($m), 2008 111

Figure 4.11: Decline trajectory of Protonix (%), 2004–08 113

Figure 4.12: Drug class focus of J&J ($m), 2008 116

List of Tables

Table 1.1: Prevalence of major GIT indications across the seven major markets, 2008 20

Table 1.2: Estimated prevalence of GERD across seven major markets, 2008 22

Table 1.3: Forecast prevalence of GERD across seven major markets, 23

Table 1.4: Estimated prevalence of PUD across seven major markets, 2008 26

Table 1.5: Forecast prevalence of PUD across seven major markets, 27

Table 1.6: Estimated prevalence of IBS across seven major markets, 2008 30

Table 1.7: Forecast prevalence of IBS across seven major markets, 31

Table 1.8: Estimated prevalence of UC across seven major markets, 2008 33

Table 1.9: Forecast prevalence of UC across seven major markets, 34

Table 1.10: Estimated prevalence of CD across seven major markets, 2008 36

Table 1.11: Forecast prevalence of CD across seven major markets, 37

Table 2.12: Distribution of the global GI market by drug class, 2007–08 47

Table 2.13: Key brands of the PPI drug class, 2008 50

Table 2.14: Key brands of the H2RA drug class, 2008 55

Table 2.15: Key brands of the intestinal anti-inflammatories drug class, 2008 58

Table 2.16: Key brands of the serotonin antagonists drug class, 2008 60

Table 2.17: Key brands of the antispasmodics/anticholinergics drug class, 2008 62

Table 2.18: Leading brands used in IBD in the seven major markets, 2008 64

Table 2.19: Key laxative brands, 2008 69

Table 2.20: GI market sales forecast by drug classes ($m), 70

Table 2.21: Leading brands of the GI market, 2008 71

Table 2.22: Top 10 brands of the GI market, sales forecast 2008–14 72

Table 3.23: Key investigational compounds in the GI market, 2009 78

Table 3.24: An overview of Entereg 79

Table 3.25: An overview of Relistor 81

Table 3.26: An overview of TAK-390MR 82

Table 3.27: An overview of linaclotide 85

Table 3.28: An overview of Cimzia 86

Table 3.29: Key GI investigational compounds sales forecast, 2008–14 88

Table 4.30: Leading players of the GI disorders market, 2008 93

Table 4.31: Leading brands of AstraZeneca, 2008 95

Table 4.32: Key pipeline compounds of AstraZeneca 96

Table 4.33: Leading brands of Takeda, 2008 100

Table 4.34: Key pipeline compounds of Takeda 101

Table 4.35: Leading brands of Eisai, 2008 104

Table 4.36: Leading brands of Nycomed, 2008 108

Table 4.37: Leading brands of Wyeth, 2008 112

Table 4.38: Key pipeline compounds of Wyeth 114

Table 4.39: Leading brands of J&J, 2008 117

Table 4.40: Key pipeline compounds of J&J 118

Table 4.41: Leading players in the GI market, sales forecast 2008–14 121

To order this report:

Pharmaceutical Industry: The Gastrointestinal Market Outlook To 2014: Market dynamics, competitive landscape, emerging therapies

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)-652-2626

Intl: +1 805-652-2626


SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com